Effects of Perampanel on Seizure Control, Cognition, Behavior, and Psychological Status in Patients With Epilepsy: A Systematic Review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Thoroughly acquainting physicians with the effects of antiseizure medications (ASMs) is essential for developing appropriate therapeutic regimens for seizure management. This review summarizes the available evidence regarding patients receiving the antiseizure agent perampanel (PER) and its effects on the cognition, behavior, and psychological status of patients. Methods The PubMed and Google Scholar databases were searched for all relevant articles published during 2015–2021 and without any other publication limitations, and also manually searched the reference lists in the identified articles. Outcomes of interest were changes in seizure frequency relative to baseline, 50% responder rate, seizure-free rate, and retention rate (proportion of participants continuing PER at study endpoints). Safety outcomes included adverse effects and the percentage of patients experiencing effects on cognitive, psychiatric, and behavioral symptoms. Results We identified 139 studies, of which 28 were included after screening. Most studies found reduced seizure frequencies and satisfactory responder and retention rates, demonstrating the effectiveness and tolerability of PER. No negative effects were found for cognitive function, but a nonnegligible impact on aggressive behavior was noted when compared with other ASMs. Patients with previous psychiatric comorbidities had a greater risk of psychiatric side effects under PER treatment. PER induces an overall improvement in quality of life. Conclusions After synthesizing the study results, PER was a safe and effective choice as an additional therapy for patients with refractory epilepsy. A comprehensive evaluation of behavior and psychiatric risk is suggested before implementing PER.
Abstract
Background and Purpose Thoroughly acquainting physicians with the effects of antiseizure medications (ASMs) is essential for developing appropriate therapeutic regimens for seizure management. This review summarizes the available evidence regarding patients receiving the antiseizure agent perampanel (PER) and its effects on the cognition, behavior, and psychological status of patients. Methods The PubMed and Google Scholar databases were searched for all relevant articles published during 2015–2021 and without any other publication limitations, and also manually searched the reference lists in the identified articles. Outcomes of interest were changes in seizure frequency relative to baseline, 50% responder rate, seizure-free rate, and retention rate (proportion of participants continuing PER at study endpoints). Safety outcomes included adverse effects and the percentage of patients experiencing effects on cognitive, psychiatric, and behavioral symptoms. Results We identified 139 studies, of which 28 were included after screening. Most studies found reduced seizure frequencies and satisfactory responder and retention rates, demonstrating the effectiveness and tolerability of PER. No negative effects were found for cognitive function, but a nonnegligible impact on aggressive behavior was noted when compared with other ASMs. Patients with previous psychiatric comorbidities had a greater risk of psychiatric side effects under PER treatment. PER induces an overall improvement in quality of life. Conclusions After synthesizing the study results, PER was a safe and effective choice as an additional therapy for patients with refractory epilepsy. A comprehensive evaluation of behavior and psychiatric risk is suggested before implementing PER.
참고문헌 (44)
- Fiest KM, "Prevalence and incidence of epilepsy : a systematic review and metaanalysis of international studies", Neurology, 88, pp.296~303 (2017)
- Žiburkus J, "Seizures as imbalanced up states : excitatory and inhibitory conductances during seizure-like events", J Neurophysiol, 109, pp.1296~1306 (2013)
- Bialer M, "Key factors in the discovery and development of new antiepileptic drugs", Nat Rev Drug Discov, 9, pp.68~82 (2010)
- Pascarella A, "The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a"real world"context : focus on temporal lobe epilepsy", J Neurol Sci, 415, pp.116903~ (2020)
- Liguori C, "Comparison of the effectiveness and tolerability of perampanel and brivaracetam : a real-world, observational, retrospective study", Epileptic Disord, 22, pp.309~316 (2020)
- Lee SA, "Effect of perampanel on aggression in patients with refractory focal epilepsy : a 6-month longitudinal study", Epilepsy Behav, 102, pp.106658~ (2020)
- Liguori C, "Efficacy and tolerability of perampanel and levetiracetam as first addon therapy in patients with epilepsy : a retrospective single center study", Epilepsy Behav, 80, pp.173~176 (2018)
- Piña-Garza JE, "Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy : post hoc analysis of six randomized studies", Epilepsy Behav, 104(Pt A), pp.106876~ (2020)
- Helmstaedter C, "Epilepsy and cognition-A bidirectional relationship?", Seizure, 49, pp.83~89 (2017)
- Petralia RS, "Light and electron immunocytochemical localization of AMPA-selective glutamate receptors in the rat brain", J Comp Neurol, 318, pp.329~354 (1992)
- Rogawski MA, "Revisiting AMPA receptors as an antiepileptic drug target", Epilepsy Curr, 11, pp.56~63 (2011)
- Hansen CC, "Mechanisms underlying aggressive behavior induced by antiepileptic drugs : focus on topiramate, levetiracetam, and perampanel", Behav Neurol, 2018, pp.2064027~ (2018)
- Wu T, "Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model", Seizure, 23, pp.732~739 (2014)
- Lattanzi S, "The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery", Expert Opin Drug Discov, 14, pp.195~197 (2019)
- Liguori C, "Perampanel increases cortical EEG fast activity in child and adult patients affected by epilepsy : a quantitative EEG study", Clin EEG Neurosci, 52, pp.360~370 (2021)
- Ahn SJ, "Effects of perampanel on cognition and quantitative electroencephalography in patients with epilepsy", Epilepsy Behav, 115, pp.107514~ (2021)
- Lee SH, "The effect of perampanel on resting-state electroencephalography functional connectivity in patients with epilepsy", Epilia : Epilepsy Commun, 3, pp.40~46 (2021)
- Lanzone J, "The effect of perampanel on EEG spectral power and connectivity in patients with focal epilepsy", Clin Neurophysiol, 132, pp.2176~2183 (2021)
- SteinhoffBJ, "Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures : a pooled analysis of three phase III studies", Epilepsia, 54, pp.1481~1489 (2013)
- Abril Jaramillo J, "Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice : Spain prospective study(PERADON)", Epilepsy Behav, 102, pp.106655~ (2020)
- Santamarina E, "Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs", Seizure, 83, pp.48~56 (2020)
- Rohracher A, "Perampanel in routine clinical use across Europe : pooled, multicenter, observational data", Epilepsia, 59, pp.1727~1739 (2018)
- French JA, "Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial", Neurology, 85, pp.950~957 (2015)
- Villanueva V, "Perampanel in routine clinical use in idiopathic generalized epilepsy : the 12-month GENERAL study", Epilepsia, 59, pp.1740~1752 (2018)
- Maschio M, "Perampanel in brain tumor-related epilepsy : observational pilot study", Brain Behav, 10, pp.e01612~ (2020)
- Lin CY, "Effectiveness and safety of perampanel in adults with mesial temporal epilepsy: a single-center postmarketing study in Taiwan", Medicine(Baltimore), 98, pp.e17171~ (2019)
- Huber B, "A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment", Epilepsy Behav, 66, pp.74~79 (2017)
- Andres E, "Behavioural changes in patients with intellectual disability treated with perampanel", Acta Neurol Scand, 136, pp.645~653 (2017)
- Chen Z, "Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs : a 30-year longitudinal cohort study", JAMA Neurol, 75, pp.279~286 (2018)
- Lin KL, "Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy : the first real-world evaluation in Asian pediatric neurology clinics", Epilepsy Behav, 85, pp.188~194 (2018)
- Kanemura H, "Effects of perampanel on secondary bilateral synchrony and behavioral problems in adolescents with epilepsy showing insufficient response with levetiracetam", Seizure, 80, pp.131~137 (2020)
- Lattanzi S, "Adjunctive perampanel in older patients with epilepsy : a multicenter study of clinical practice", Drugs Aging, 38, pp.603~610 (2021)
- Meschede C, "Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting", Seizure, 58, pp.141~146 (2018)
- Rea R, "Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy : a retrospective study", Epilepsy Behav, 98(Pt A), pp.139~144 (2019)
- Piña-Garza JE, "Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures", Epilepsy Behav, 83, pp.50~58 (2018)
- Moraes JS, "Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy", Epilepsy Behav, 104(Pt A), pp.106883~ (2020)
- Operto FF, "Perampanel tolerability in children and adolescents with focal epilepsy : effects on behavior and executive functions", Epilepsy Behav, 103(Pt A), pp.106879~ (2020)
- Goji H, "The effect of perampanel on aggression and depression in patients with epilepsy : a short-term prospective study", Seizure, 67, pp.1~4 (2019)
- Juhl S, "Add-on perampanel and aggressive behaviour in severe drug-resistant focal epilepsies", Funct Neurol, 32, pp.215~220 (2017)
- Rosenfeld W, "Efficacy and safety of perampanel in adolescent patients with drugresistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study", Eur J Paediatr Neurol, 19, pp.435~445 (2015)
- Stephen LJ, "Psychiatric side effects and antiepileptic drugs : observations from prospective audits", Epilepsy Behav, 71(Pt A), pp.73~78 (2017)
- Hasegawa N, "Differences in levetiracetam and perampanel treatment-related irritability in patients with epilepsy", Epilepsy Behav, 116, pp.107644~ (2021)
- von Wrede R, "Levetiracetam, perampanel, and the issue of aggression : a self-report study", Epilepsy Behav, 117, pp.107806~ (2021)
- 윤송이, "Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy", Journal of Clinical Neurology, 14(3), pp.296~302 (2018), 대한신경과학회[DOI]